$BSEM News

BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options

BioStem Technologies Files Prospectus Related To The Resale Of Up To 2.2M Shares By Selling Stockholders

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

BioStem Secures US Patent, Additional US And Mexico Allowances For Tissue Technologies

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform

BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility

BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier

BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal

BioStem Technologies to Present at the Sidoti MicroCap Conference

BioStem Technologies Inc (BSEM) (Q2 2026) Earnings Call Highlights: Revenue Surges to $7. ...

BioStem Technologies Q2 Earnings Call Highlights

BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates

BioStem Technologies Reports Second Quarter 2026 Financial Results

BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript

BioStem Technologies Q2 EPS $(0.52), Sales $7.899M Down From $10.963M YoY

BioStem Technologies Announces Nasdaq Uplisting

BioStem Technologies Announces Nasdaq Uplisting

BioStem Technologies Announces It Received Nasdaq Approval For The Company’s Common Stock For Listing On The Nasdaq Capital Market; Co. To Begin Trading On Nasdaq On August 7, 2026 Under The Ticker Symbol "BSEM"